{"analyses":[{"ciLowerLimit":"-7.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.4","estimateComment":"Difference in percentages calculated as % Women 27-45 Years of Age minus % Women 16-26 Years of Age.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Difference in Percentages","paramValue":"-1.9"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.3"},{"groupId":"OG001","value":"64.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"570"},{"groupId":"OG001","value":"640"}],"units":"Participants"}],"description":"An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Systemic AEs are those not categorized as injection-site AEs. The percentage of participants that reported at least 1 systemic AE was assessed","groups":[{"description":"Young adult women 16- to 26-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG000","title":"Women 16-26 Years of Age"},{"description":"Adult women 27- to 45-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG001","title":"Women 27-45 Years of Age"}],"paramType":"NUMBER","populationDescription":"All participants that received at least 1 vaccination and had available data for endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 15 days post any vaccination","title":"Percentage of Participants That Reported at Least 1 Systemic Adverse Event","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}